Holmusk and Charité – Universitätsmedizin Berlin enter strategic collaboration to boost precision psychiatry using new real-world data
BERLIN, 23 November 2021 / PRNewswire / – Holmusk, a leading global data science and digital health company building the world’s largest real-world evidence (RWE) platform for mental health , signed a memorandum of understanding with Charité – Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, to embark on an innovative research partnership. The collaboration aims to enable precision psychiatry for patients, by capturing and analyzing real-world data. This groundbreaking initiative is expected to improve the much needed understanding of psychiatric disorders, a complex clinical area where research evidence always lags behind other therapeutic areas.
Holmusk will work with three departments of Charité, namely the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, the Departments of Psychiatry and Neuroscience of Campus Charité. Mitte and Campus Benjamin Franklin, as well as the Department of Social and Preventive Medicine at the University of Potsdam, each of whom are members of the Charité Mental Health Platform and the Berlin site of the brand new German Mental Health Center (DZP). The German Center for Mental Health is a pioneering government-funded center structure made up of 6 German sites aimed at further improving the quality of care for people with mental illness in Germany.
The strategic collaboration is focused on creating a multi-site and standardized real-world data capture infrastructure, including assessments and reported outcomes by clinicians and patients. The selected and digitized data will enable improved, real-time quality assessment and form the basis of measurement-based care in Germany. Additionally, the envisioned and widely implemented RWE platform could enable large German real-world studies on a scale that is currently only possible in Europe in the Scandinavian countries. An essential element of this initiative is the rigorous application of the highest standards of security and data protection, including the strict implementation of the provisions of the GDPR. This forward-thinking initiative is made possible by the partnership between Charité and Holmusk, a world leader in real-world data science in psychiatry.
In addition to improving clinical care, this comprehensive real-world data initiative aims to advance precision psychiatry through the identification of clinical markers that can take advantage of the wide heterogeneity of patients and outcomes in clinical practice. and thereby improve diagnosis and further personalize treatment plans. The demand for better mental health care has increased further since the start of the COVID-19 pandemic, as the focus has widened towards mental well-being for all.
“This Holmusk-Mental Health Services of Charity Collaboration is such an important initiative to move psychiatry towards a data-driven approach and enable us to develop improved evidence based on real-world patients being treated in real-world settings ”, said the teacher Christoph Correll, Director of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy of Charité, “Holmusk’s advanced data science capabilities provide an exciting opportunity to better monitor disease progression and response to treatment at the patient level. “
“We are honored to be the partner of choice for these important members of the Charity Mental Health Platform and to combine their in-depth clinical and research expertise with our advanced data science capabilities.” noted Stefan Suter, the leader of Holmusk Europe, “This collaboration has the potential to significantly advance the treatment of patients with psychiatric disorders.”
Holmusk’s mission is to reinvent behavioral health and transform lives with real world evidence and digital innovation. Based in Singapore and New York, Holmusk generates evidence and creates digital solutions to advance research, innovation and care in behavioral health.
Holmusk’s flagship product NeuroBlu synthesizes real-world data (RWD) with transparent analytics tools, enabling users to create actionable insights that drive behavioral health transformation. NeuroBlu is powered by a state-of-the-art and ever-evolving behavioral health clinical data set, with over 20 years of data from over 560,000 patients and over 20 million encounters. Holmusk uses advanced proprietary analytics to enrich data, with natural language processing and disease predictive models designed specifically for mental health. Holmusk enriches its data and analytics offerings with powerful digital solutions that improve patient engagement, support disease self-management, and capture patient-reported outcomes to help guide clinical decisions and analyzes. For more information, please visit www.holmusk.com.
About Charity – Universitätsmedizin Berlin
Charity – Universitätsmedizin Berlin is one of the largest teaching hospitals in Europe, offering 3,001 beds and comprising around 100 departments and institutes spread over 4 separate campuses. With a total of 19,400 employees in its group of companies (including 16,391 at Charité), the organization is one of the largest employers in Berlin. At Charité, the fields of research, education and medical care are closely linked. 4,707 of its employees work in nursing, and another 4,693 in research and medical care. Last year, Charité treated 132,383 inpatients and day care patients, in addition to 655,138 outpatients. In 2020, Charité achieved a turnover of around 2.2 billion euros (including external funding and investment grants) and set a new record by securing 196 million euros in external funding. The Faculty of Medicine of Charité is one of the most Germany, educating and training more than 8,600 students in medicine, dentistry and the health sciences. La Charité also offers 577 training positions in 10 different healthcare professions. For more information see www.charite.de.